Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
| Last: | $1.6487 |
|---|---|
| Change Percent: | 7.41% |
| Open: | $1.52 |
| Close: | $1.535 |
| High: | $1.6488 |
| Low: | $1.52 |
| Volume: | 528,180 |
| Last Trade Date Time: | 03/09/2026 12:45:55 pm |
| Market Cap: | $49,225,997 |
|---|---|
| Float: | 15,493,567 |
| Insiders Ownership: | 7.05% |
| Institutions: | 12 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://WWW.acrivon.com |
| Country: | US |
| City: | Watertown |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Acrivon Therapeutics Inc. (NASDAQ: ACRV).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
